Director, Head of Investigative Toxicology
Nurix Therapeutics
Director, Head of Investigative Toxicology
Nurix Therapeutics
Drug discovery targeting ubiquitin E3 ligases
Director, Head of Investigative Toxicology
Build Nurix’s in-house in vitro toxicology capability from the ground up. As Director, Head of Investigative Toxicology, you’ll establish the assays, infrastructure and mechanistic understanding to identify target- and modality-related safety liabilities earlier in discovery, shaping lead selection for our growing pipeline of targeted protein degrader programs. This is a hands-on, lab-based leadership role.
Position Description
The Opportunity
Nurix Therapeutics is seeking a Head of Investigative Toxicology to establish and lead our in-house in vitro toxicology testing capability. Reporting into the Preclinical Toxicology leadership team, this individual will build the assays, infrastructure, and mechanistic understanding needed to characterize target- and modality-related safety liabilities earlier in discovery, reducing reliance on external CROs for early screening and de-risking. This is a hands-on, lab-based leadership role for a scientist who wants to build a function from the ground up, working in close partnership with Discovery Biology, Chemistry, DMPK, and Pharmacology to inform lead selection and optimization for our growing pipeline of targeted protein degrader programs. The position reports to the Senior Vice President, Nonclinical Toxicology.
In Vitro Toxicology Capability Build
Investigative & Mechanistic Toxicology
Team & Culture
What You’ll Bring
Required Qualifications
Preferred Qualifications
Salary Range: $240,100 - $281,700
The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.
Location: Onsite – Brisbane, CA
Fit with Nurix Culture and Values
About Nurix Therapeutics
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.
Explore more opportunities at Nurix Therapeutics